File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The proarrhythmic risk of cell therapy for cardiovascular diseases

TitleThe proarrhythmic risk of cell therapy for cardiovascular diseases
Authors
Liu, YTse, HF
Keywordscardiac regeneration
cardiovascular diseases
proarrhythmia
stem cell
transplantation
Issue Date2011
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=2
Citation
Expert Review Of Cardiovascular Therapy, 2011, v. 9 n. 12, p. 1593-1601 How to Cite?
DOI: http://dx.doi.org/10.1586/erc.11.171
AbstractStem cell therapy is an emerging therapeutic approach for the treatment of cardiovascular diseases. Experimental studies have demonstrated that different types of stem cells, including bone marrow-derived cells, mesenchymal stem cells, skeletal myoblasts, and cardiac progenitor cells and embryonic stem cells, can improve cardiac function after myocardial injuries. Nevertheless, the potential proarrhythmic risk after stem cell transplantation remains a major concern. Several mechanisms, including the immaturity of electrical phenotypes of the transplanted cardiomyocytes, poor cell-cell coupling and cardiac nerve sprouting, may contribute to arrhythmogenic risk after stem cell transplantation. This review summarizes the potential theoretical arrhythmogenic mechanisms associated with different types of stem cells for the treatment of cardiovascular diseases. Nevertheless, current experimental and clinical data on the proarrhythmic risk for different types of stem cell transplantation are limited, and await further experimental and clinical investigation. © 2011 Expert Reviews Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163428
ISSN
1477-9072
2020 SCImago Journal Rankings: 0.809
ISI Accession Number ID
WOS:000216612500017
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorLiu, Yen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-09-05T05:31:15Z-
dc.date.available2012-09-05T05:31:15Z-
dc.date.issued2011en_US
dc.identifier.citationExpert Review Of Cardiovascular Therapy, 2011, v. 9 n. 12, p. 1593-1601en_US
dc.identifier.issn1477-9072en_US
dc.identifier.urihttp://hdl.handle.net/10722/163428-
dc.description.abstractStem cell therapy is an emerging therapeutic approach for the treatment of cardiovascular diseases. Experimental studies have demonstrated that different types of stem cells, including bone marrow-derived cells, mesenchymal stem cells, skeletal myoblasts, and cardiac progenitor cells and embryonic stem cells, can improve cardiac function after myocardial injuries. Nevertheless, the potential proarrhythmic risk after stem cell transplantation remains a major concern. Several mechanisms, including the immaturity of electrical phenotypes of the transplanted cardiomyocytes, poor cell-cell coupling and cardiac nerve sprouting, may contribute to arrhythmogenic risk after stem cell transplantation. This review summarizes the potential theoretical arrhythmogenic mechanisms associated with different types of stem cells for the treatment of cardiovascular diseases. Nevertheless, current experimental and clinical data on the proarrhythmic risk for different types of stem cell transplantation are limited, and await further experimental and clinical investigation. © 2011 Expert Reviews Ltd.en_US
dc.languageengen_US
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=2en_US
dc.relation.ispartofExpert Review of Cardiovascular Therapyen_US
dc.subjectcardiac regeneration-
dc.subjectcardiovascular diseases-
dc.subjectproarrhythmia-
dc.subjectstem cell-
dc.subjecttransplantation-
dc.subject.meshAdulten_US
dc.subject.meshAdult Stem Cells - Cytology - Transplantationen_US
dc.subject.meshAnimalsen_US
dc.subject.meshArrhythmias, Cardiac - Etiologyen_US
dc.subject.meshCardiovascular Diseases - Physiopathology - Therapyen_US
dc.subject.meshCell Differentiationen_US
dc.subject.meshHeart Failure - Etiology - Prevention & Control - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshMyocytes, Cardiac - Cytology - Transplantationen_US
dc.subject.meshStem Cell Transplantation - Adverse Effectsen_US
dc.subject.meshTransplantation, Autologousen_US
dc.titleThe proarrhythmic risk of cell therapy for cardiovascular diseasesen_US
dc.typeArticleen_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1586/erc.11.171en_US
dc.identifier.pmid22103878-
dc.identifier.scopuseid_2-s2.0-82755161193en_US
dc.identifier.hkuros225174-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-82755161193&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue12en_US
dc.identifier.spage1593en_US
dc.identifier.epage1601en_US
dc.identifier.isiWOS:000216612500017-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiu, Y=36071722500en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US
dc.identifier.issnl1477-9072-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats